eis promoter C14G and C15G mutations do not confer kanamycin resistance in Mycobacterium tuberculosis

10Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We studied the significance of particular eis mutations on Mycobacterium tuberculosis drug resistance using a specialized transduction strategy. Recombinant strains harboring eis promoter mutations C14T, C12T, and G10A exhibited kanamycin resistance with MICs of 40, 10, and 20 μg/ml, respectively, while recombinant strains harboring C14G and C15G mutations were kanamycin susceptible (MIC, 2.5 to 5 μg/ml). Each of the eis mutants tested remained amikacin susceptible (MIC, 0.5 to 4 μg/ml). The identification of specific eis mutations is needed for accurate genotypic susceptibility testing for kanamycin.

Cite

CITATION STYLE

APA

Pholwat, S., Stroup, S., Heysell, S., Ogarkov, O., Zhdanova, S., Ramakrishnan, G., & Houpt, E. (2016). eis promoter C14G and C15G mutations do not confer kanamycin resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 60(12), 7522–7523. https://doi.org/10.1128/AAC.01775-16

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free